Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug may shield breast cancer patients from uterine thickening

NCT ID NCT07145827

Disease control Sponsor: Uruk University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether metformin, a common diabetes drug, can reduce the thickening of the uterine lining caused by tamoxifen in postmenopausal breast cancer survivors. Sixty women who had been taking tamoxifen for at least a year were given either metformin or a placebo for 12 months. Researchers measured their endometrial thickness with ultrasound at regular visits to see if metformin made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin
What this could lead to
If it works, this could offer a way to manage a common side effect of tamoxifen, potentially reducing the risk of endometrial cancer in breast cancer survivors.
What could go wrong
This is a small, completed trial with only 60 participants. The results may not apply to all patients, and metformin can cause gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jan 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Postmenopausal Female patients (amenorrhea ≥ 12 months). * Histologically proven (Estrogen-positive) breast cancer. * Completed all required surgery and/or chemotherapy (if indicated) * On adjuvant tamoxifen for at least 1 year. * Accepts to enroll in the study Exclusion Criteria: * Refusing to enroll in the study * Ongoing or History of: endometrial or ovarian malignancy * Concurrent hormonal therapy that might affect endometrial thickness * Concurrent Diabetes mellitus in which metformin is prescribed. * Known hypersensitivity or severe intolerance to metformin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Endometrial Hyperplasia endometrium neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Endometrial hyperplasia and endometrial cancers

Contacts and locations

Locations

  • Baghdad Medical City / Department of Oncology

    Baghdad, Baghdad Governorate, 10045, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.